Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises NeuroNova AB in relation to the merger with Newron Pharmaceuticals S.p.A.
Mandate

Vinge advises NeuroNova AB in relation to the merger with Newron Pharmaceuticals S.p.A.

June 13, 2012

Vinge has advised NeuroNova AB in connection with the merger with Newron Pharmaceuticals S.p.A (”Newron”). NeuroNova AB is a research company within the biotechnology and pharmaceuticals industry which primarily develops therapies for illnesses caused by the death of cells in the central nervous system. Newron is a research company within biotechnology and is listed on the Swiss stock exchange (SIX).

Vinge’s team consisted of, among others, responsible partner Johan Winnerblad and associates Matthias Pannier and Alex Miler.

Related

Vinge has advised Aspira Partners on the establishment of Aspira Fund I

 Vinge has advised Aspira Partners ("Aspira") on the establishment and fundraising of Aspira's inaugural blind-pool fund, Aspira Fund I (D) AB and Aspira Fund I (E) AB (collectively, "Fund I" or the "Fund").
August 31, 2026

Vinge advises Consolid Equity on the sale of Road Mobility Services to Nalka

 Vinge has advised Consolid Equity on the sale of Road Mobility Services to Nalka. In connection with the transaction, Consolid, entrepreneurs and management will reinvest and remain as minority shareholders alongside Nalka as the new majority shareholder.
August 28, 2026

Vinge advises IK Partners and Selatek in connection with the acquisition of Jamo Sikring

 Vinge advises IK Partners and their portfolio company Selatek AB ("Selatek") in connection with the acquisition of JAMO SIKRING A/S ("Jamo Sikring"), a Danish specialist in the installation, maintenance and ongoing inspection of fire protection systems. The acquisition marks Selatek's establishment of operations in Denmark and strengthens the group's position in fire safety and security services in the Nordics.
August 21, 2026